No fads. No fearmongering. Just the stuff that works.
Retatrutide
Retatrutide's triple-hormone trial results look bigger than tirzepatide's, but they come from separate studies, not a head-to-head. And one drug is approved while the other is still investigational. Here's the honest comparison.
By Tony Dalton
What the retatrutide trials reported about side effects, where the drug sits in development, and a clear warning about unregulated online versions. General info, not medical advice.
An honest look at retatrutide, Eli Lilly's investigational GIP/GLP-1/glucagon triple agonist: what trials show, its status, and sourcing risks.